Form D · Biotechnology

Genomenon, Inc.

Ann Arbor, MI · CIK 0001650557

Offering snapshot reported Jul 30, 2026 · SEC filing

Reported sold
$6.03M
Offering amount: $10M
Investors reported
30
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 15, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 30, 2026Initial$6,025,002No comparison30SEC filing
May 16, 2024Initial$5,461,759No comparison30SEC filing
Mar 10, 2022Initial$19,999,994No comparison23SEC filing
May 21, 2020Initial$2,885,877No comparison36SEC filing
Aug 14, 2015Initial$446,003No comparison11SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-592635

Source: Form D, filed Jul 30, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Patricia Glaza Director
Sam Globus Executive
David Gregorka Director
Brian Groark Executive
Michael Gross Director
Sean Kearney Executive
Mark Kiel Director, Executive
Michael Klein Director, Executive
Charles Moret Director
Eli Salembier Director, Executive
Steve Schwartz Executive
Sonya Sepahban Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
206 E. Huron Street Suite 114
Ann Arbor, MI, 48104
Phone: 734-794-3075